FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC

Akinboro, O; Larkins, E; Pai-Scherf, LH; Mathieu, LN; Ren, Y; Cheng, J; Fiero, MH; Fu, WT; Bi, YW; Kalavar, S; Jafri, S; Mishra-Kalyani, PS; Zirkelbach, JF; Li, HS; Zhao, H; He, K; Helms, WS; Chuk, MK; Wang, M; Bulatao, I; Herz, J; Osborn, BL; Xu, Y; Liu, J; Gong, YT; Sickafuse, S; Cohen, R; Donoghue, M; Pazdur, R; Beaver, JA; Singh, H

Akinboro, O (通讯作者)，US FDA, Div Oncol 2, Off Oncol Dis, Ctr Drug Evaluat & Res CDER, 10903 New Hampshire Ave, Silver Spring, MD 20993 USA.

CLINICAL CANCER RESEARCH, 2022; 28 (11): 2221

Abstract

FDA's approval of cemiplimab-rwlc on February 22, 2021, follows prior approvals of pembrolizumab and atezolizumab for similar indications as first-lin......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索